Clinical Trial Update: ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports the completion of a study evaluating atezolizumab, bevacizumab, and chemotherapy in EGFR-mutant stage IIIB/C or IV non-squamou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | Phase 2 | Status: COMPLETED